This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: Scott Gangloff: Innovator in Protein Production Processes
Introduction
Scott Gangloff is a notable inventor based in Bensalem, Pennsylvania. He has made significant contributions to the field of protein production, particularly through his innovative methods for enhancing product quality in mammalian cell culture processes.
Latest Patents
Scott Gangloff holds a patent for a method that focuses on product quality enhancement in mammalian cell culture processes for protein production. This invention describes techniques for producing proteins, especially glycoproteins, by utilizing animal or mammalian cell cultures, particularly in fed-batch systems. The methods involve feeding cells with D-galactose to maintain effective sialylation levels throughout the culture duration. Additionally, the invention includes temperature shifts during the culturing period to sustain high cell viability and extend the protein production phase. The delayed addition of polyanionic compounds is also part of the process, which is beneficial for large-scale culturing.
Career Highlights
Scott Gangloff is currently employed at Bristol-Myers Squibb Company, where he applies his expertise in protein production processes. His work has contributed to advancements in biopharmaceutical manufacturing, enhancing the quality and efficiency of protein production.
Collaborations
Some of Scott's coworkers include Bernhard M. Schilling and Dharti Kothari, who collaborate with him on various projects related to protein production and cell culture processes.
Conclusion
Scott Gangloff's innovative approaches to protein production through mammalian cell culture processes highlight his significant role in the field. His contributions continue to impact biopharmaceutical manufacturing positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
